Anuraj Nayarisseri

Dr. Anuraj Nayarisseri

Bioinformatics, Alagappa University, Karaikudi, India
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
Anuraj NayarisseriAnuraj Nayarisseri
Anuraj Nayarisseri
RKRavina Khandelwal
Ravina Khandelwal
PTPoonam Tanwar
Poonam Tanwar
MMMaddala Madhavi
Maddala Madhavi
DSDiksha Sharma
Diksha Sharma
SSSanjeev Kumar Singh
Sanjeev Kumar Singh
Artificial Intelligence revolutionizes the drug development process that can quickly identify potential biologically active compounds from millions of candidate within a short period. The present review is an overview based on some applications of Machine Learning based tools, such as GOLD, Deep PVP, LIB SVM, etc. and the algorithms involved such as support vector machine (SVM), random forest (RF), decision tree and Artificial Neural Network (ANN), etc. at various stages of drug designing and development. These techniques can be employed in SNP discoveries, drug repurposing, ligand-based drug design (LBDD), Ligand-based Virtual Screening (LBVS) and Structure- based Virtual Screening (SBVS), Lead identification, quantitative structure-activity relationship (QSAR) modeling, and ADMET analysis. It is demonstrated that SVM exhibited better performance in indicating that the classification model will have great applications on human intestinal absorption (HIA) predictions. Successful cases have been reported which demonstrate the efficiency of SVM and RF models in identifying JFD00950 as a novel compound targeting against a colon cancer cell line, DLD-1, by inhibition of FEN1 cytotoxic and cleavage activity. Furthermore, a QSAR model was also used to predict flavonoid inhibitory effects on AR activity as a potent treatment for diabetes mellitus (DM), using ANN. Hence, in the era of big data, ML approaches have been evolved as a powerful and efficient way to deal with the huge amounts of generated data from modern drug discovery to model small-molecule drugs, gene biomarkers and identifying the novel drug targets for various diseases.

2 September 2014 in SpringerPlus
Verified
Journal Article
Open access
PDF file
MBMayuri Bhatia
Mayuri Bhatia
AGAmandeep Girdhar
Amandeep Girdhar
ATArchana Tiwari
Archana Tiwari
Anuraj NayarisseriAnuraj Nayarisseri
Anuraj Nayarisseri
Degradation of Petroleum-plastics like Low Density Polyethylene (LDPE) is a budding challenge due to increasing white pollution. The present investigation has focused the aspect through microbial assisted biodegradation. Various indigenous microorganisms were isolated from collected municipal landfill soil. Growth medium enriched with 0.2 g of LDPE powder was used to screen the soil bacteria with biodegradation potential. The screened bacteria were subjected to biodegradation assay in presence of LDPE sheets in growth medium. Four strains gave 5%, 17.8%, 0.9% and 0.6% degradation rate based on weight loss in the conducted in vitro assay for four days. The maximum degraded sheet was analyzed through Scanning Electron Microscopy, Fourier transform infrared spectroscopy and Thermogravimetry, taking undegraded LDPE sheet as control. Results illustrated one-step weight loss with control and three-step weight loss with test. Thus, it proved the efficacy of isolated strain. The strain identification was carried out by genomic DNA isolation followed by PCR and 16S rRNA sequencing. Genotypic identification revealed the bacterium as Pseudomonas citronellolis. BLAST gave a similarity with the database of 96%, thus phylogenetic assessment clarified the bacterium as a novel strain. The isolate was named as Pseudomonas citronellolis EMBS027 and sequence was deposited as LDPE degrading species, in GenBank with accession number KF361478.

1 January 2018 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Alex France Messias MonteiroAlex France Messias Monteiro
Alex France Messias Monteiro
JVJéssika De O Viana
Jéssika De O Viana
Anuraj NayarisseriAnuraj Nayarisseri
Anuraj Nayarisseri
EZErnestine NkwengouaTchouboun Zondegoumba
Ernestine NkwengouaTchouboun Zondegoumba
Francisco Mendonça JuniorFrancisco Mendonça Junior
Francisco Mendonça Junior
LUCIANA SCOTTILUCIANA SCOTTI
LUCIANA SCOTTI
Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s, are understood as occurring through genetic, cellular, and multifactor pathophysiological mechanisms. Several natural products such as flavonoids have been reported in the literature for having the capacity to cross the blood‐brain barrier and slow the progression of such diseases. The present article reports on in silico enzymatic target studies and natural products as inhibitors for the treatment of Parkinson’s and Alzheimer’s diseases. In this study we evaluated 39 flavonoids using prediction of molecular properties and in silico docking studies, while comparing against 7 standard reference compounds: 4 for Parkinson’s and 3 for Alzheimer’s. Osiris analysis revealed that most of the flavonoids presented no toxicity and good absorption parameters. The Parkinson’s docking results using selected flavonoids as compared to the standards with four proteins revealed similar binding energies, indicating that the compounds 8‐prenylnaringenin, europinidin, epicatechin gallate, homoeriodictyol, capensinidin, and rosinidin are potential leads with the necessary pharmacological and structural properties to be drug candidates. The Alzheimer’s docking results suggested that seven of the 39 flavonoids studied, being those with the best molecular docking results, presenting no toxicity risks, and having good absorption rates (8‐prenylnaringenin, europinidin, epicatechin gallate, homoeriodictyol, aspalathin, butin, and norartocarpetin) for the targets analyzed, are the flavonoids which possess the most adequate pharmacological profiles.

1 April 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
KPKhushboo Patidar
Khushboo Patidar
UPUmesh Panwar
Umesh Panwar
SVSugunakar V
Sugunakar V
JSJajoriya Sweta
Jajoriya Sweta
MSManpreet Kaur Sandhu
Manpreet Kaur Sandhu
SSSanjeev Kumar Singh
Sanjeev Kumar Singh
Breast cancer is the most frequent malignancy among women. It is a heterogeneous disease with different subtypesdefined by its hormone receptor. A hormone receptor is mainly concerned with the progression of the PI3K/AKT/mTOR pathway which is often dysregulated in breast cancer. This is a major signaling pathway that controls theactivities such as cell growth, cell division, and cell proliferation. The present study aims to suppress mTOR proteinby its various inhibitors and to select one with the highest binding affinity to the receptor protein. Out of 40 inhibitorsof mTOR against breast cancer, SF1126 was identified to have the best docking score of -8.705, using SchrodingerSuite which was further subjected for high throughput screening to obtain best similar compound using Lipinski’sfilters. The compound obtained after virtual screening, ID: ZINC85569445 is seen to have the highest affinity withthe target protein mTOR. The same result based on the binding free energy analysis using MM-GBSA showed thatthe compound ZINC85569445 to have the the highest binding free energy. The next study of interaction between theligand and receptor protein with the pharmacophore mapping showed the best conjugates, and the ZINC85569445 canbe further studied for future benefits of treatment of breast cancer.

1 June 2016 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
KPKavisha Patidar
Kavisha Patidar
ADAruna Deshmukh
Aruna Deshmukh
SBSrinivas Bandaru
Srinivas Bandaru
CLChandana Lakkaraju
Chandana Lakkaraju
AGAmandeep Girdhar
Amandeep Girdhar
SSSanjeev Kumar Singh
Sanjeev Kumar Singh
Virtual Screening Approaches in Identification of Bioactive Compounds Akin to Delphinidin as Potential HER2 Inhibitors for the Treatment of Breast Cancer Delphinidin;HER2;breast cancer;virtual screening;molecular docking; Small molecule tyrosine kinase inhibitors targeting HER 2 receptors have emerged as an important therapeutic approach in inhibition of downstream proliferation and survival signals for the treatment of breast cancers. Recent drug discovery efforts have demonstrated that naturally occurring polyphenolic compounds like delphinidin have potential to inhibit proliferation and promote apoptosis of breast cancer cells by targeting HER2 receptors. While delphinidin may thus reduce tumour size, it is associated with serious side effects like dysphonia. Owing to the narrow therapeutic window of delphinidin, the present study aimed to identify high affinity compounds targeting HER2 with safer pharmacological profiles than delphinidin through virtual screening approaches. Delphinidin served as the query parent for identification of structurally similar compounds by Tanimoto-based similarity searching with a threshold of 95% against the PubChem database. The compounds retrieved were further subjected to Lipinski and Verber's filters to obtain drug like agents, then further filtered by diversity based screens with a cut off of 0.6. The compound with Pubchem ID: 91596862 was identified to have higher affinity than its parent. In addition it also proved to be non-toxic with a better ADMET profile and higher kinase activity. The compound identified in the study can be put to further in vitro drug testing to complement the present study.

3 November 2018 in International Journal of Environmental Science and Technology
Verified
Journal Article
Closed access
PDF file
Anuraj NayarisseriAnuraj Nayarisseri
Anuraj Nayarisseri
PSP. Singh
P. Singh
SSSanjeev Kumar Singh
Sanjeev Kumar Singh